Rituximab

Generic Name
Rituximab
Brand Names
MabThera, Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima, Blitzima, Rixathon, Riximyo
Drug Type
Biotech
Chemical Formula
-
CAS Number
174722-31-7
Unique Ingredient Identifier
4F4X42SYQ6
Background

Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , . It was originally approved by the U...

Indication

Rituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in pat...

Associated Conditions
Active, Moderate to Severe Rheumatoid Arthritis, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma, Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA), Advanced Burkitt Lymphoma (BL), Advanced Burkitt-like lymphoma, Advanced Diffuse Large B-Cell Lymphoma (DLBCL), Advanced Mature B-cell type acute leukaemia, Moderate Pemphigus Vulgaris (PV), Non-progressive Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory follicular B-cell non-Hodgkin's lymphoma, Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL), Relapsed follicular B-cell non-Hodgkin's lymphoma, Severe Pemphigus Vulgaris (PV)
Associated Therapies
-
pharmacytimes.com
·

Clinical Safety Data Show Switching Between Rituximab Biosimilars Does Not Increase Adverse Event Risk

A study in Cancers found switching between rituximab biosimilars does not increase adverse event risk. The study involved 505 patients with NHL and CLL, who received 3681 infusions, 77% biosimilars. ARs occurred in 16.8% of patients, more common in indolent NHL, and were associated with age and neutrophil count. No significant difference in ARs between those who switched and those who did not.
curetoday.com
·

The FDA Approves Labeling Update for Sandoz in the Treatment of B-Cell CLL

The FDA approved updated drug labeling for Sandoz's fludarabine phosphate injection in B-cell CLL under Project Renewal, removing a boxed warning and revising dosing regimens.
pharmabiz.com
·

Roche to present more than 40 abstracts across nine blood disorders at the 66th ASH meeting

Roche to present over 40 abstracts on nine blood disorders at ASH 2024, highlighting long-term follow-up data for Polivy, Lunsumio, and Columvi, and new investigational combinations. Key findings include durable remissions and positive trends in overall survival for DLBCL, long-lasting remissions and immune recovery for FL and DLBCL, and potential benefits of subcutaneous Lunsumio. Patient-reported outcomes support Columvi's benefits in DLBCL. Roche continues to innovate in hematology with a broad portfolio and pipeline.

Genentech to present blood disorders data at ASH

Genentech to present over 40 abstracts on blood disorders at ASH 2023, highlighting long-term follow-up data for Polivy, Lunsumio, and Columvi, showing durable remissions and potential OS improvements in DLBCL. New subcutaneous Lunsumio data indicate deep, durable responses and low cytokine release syndrome. Patient-reported outcomes from STARGLO study support Columvi's benefits in DLBCL. Updated data on Polivy combinations with bispecific antibodies suggest potential in earlier treatment lines.
morningstar.com
·

Genentech to Present New and Encouraging Long-term Follow-up Data Across ...

Genentech to present over 40 abstracts on long-term follow-up data for its hematology portfolio at ASH 2024, including five-year data from the POLARIX study showing Polivy's potential in first-line DLBCL, extended follow-up data for Lunsumio and Columvi demonstrating long-lasting remissions, and new patient-reported outcomes from the STARGLO study.

Potential for peptides to replace antibodies in radiopharma, says WuXi AppTec exec

WuXi AppTec’s Dr Dave Madge predicts peptide-based radiotherapeutics could surpass antibody-based counterparts due to advantages like tissue penetration and low toxicity. Despite only two antibody-based radiopharmaceuticals being FDA-approved, the radiopharmaceutical space has seen significant deals, with theranostic radiopharmaceuticals combining diagnostics and therapy gaining traction. WuXi’s expansion in peptide manufacturing aims to meet global demand, but potential restrictions from the US BIOSECURE Act pose a challenge.
openpr.com
·

Red Biotechnology Market Global Trends Evaluation

The Red Biotechnology Market is projected to grow at a CAGR of 5.2% by 2031, driven by advancements in pharmaceuticals, vaccines, and diagnostics. Key players include Hoffmann-La Roche, Ltd., Merck KGaA, and Regeneron Pharmaceuticals, Inc. The market is segmented by product type, application, and end user, with regional focus on North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.
© Copyright 2024. All Rights Reserved by MedPath